Global Stem Cell Umbilical Cord Blood Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Stem Cell Umbilical Cord Blood Market Analysis

The stem cell umbilical cord blood market has been experiencing significant growth due to its potential in treating a variety of diseases, including cancers, blood disorders, and immune system conditions. This market has seen considerable advancements, particularly in the areas of research and technology that enhance the storage, processing, and application of stem cells. Breakthroughs in genetic engineering, cell therapy, and regenerative medicine have expanded the possibilities for umbilical cord blood, leading to increased demand from hospitals and research institutions. The market is bolstered by improved healthcare infrastructure and policies supporting stem cell-based therapies, particularly in regions such as North America and Asia-Pacific. North America remains the dominant region due to strong R&D investment and favorable reimbursement policies, while Asia-Pacific is expected to witness the highest growth due to rising chronic disease prevalence and improving medical infrastructure. Technological advancements, such as innovative cell processing techniques and automated storage solutions, have improved the efficiency and yield of stem cell collection. These developments contribute to better patient outcomes and more widespread use of cord blood for regenerative medicine. The growing awareness of stem cell benefits and increased funding for research are further fueling market expansion and driving innovations in treatment methodologies.

Stem Cell Umbilical Cord Blood Market Size

The global stem cell umbilical cord blood market size was valued at USD 6.20 billion in 2024 and is projected to reach USD 15.39 billion by 2032, with a CAGR of 12.04% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Stem Cell Umbilical Cord Blood Market Trends

“Increasing Focus on Regenerative Medicine”

One notable trend in the stem cell umbilical cord blood market is the increasing focus on regenerative medicine and its applications in treating chronic diseases. Companies are leveraging advancements in stem cell technology to expand the therapeutic use of cord blood beyond traditional hematopoietic stem cell transplants. For instance, in recent years, CBR Systems, Inc. has collaborated with NantKwest Inc. to explore innovative treatments for COVID-19 using umbilical cord-derived mesenchymal stem cells (MSCs). This type of stem cell has shown potential in reducing inflammation and promoting tissue repair, demonstrating the growing role of cord blood in addressing blood disorders and immune system conditions and chronic diseases. Moreover, as LifeCell International introduced new processing techniques to increase stem cell yield, the market has seen more efficient and effective cord blood storage solutions. This trend underscores the evolution of cord blood from a simple storage service to a vital component in advanced medical treatments.

Report Scope and Stem Cell Umbilical Cord Blood Market Segmentation         

Stem Cell Umbilical Cord Blood Market Definition

Stem cell umbilical cord blood refers to the rich source of stem cells found in the blood of the umbilical cord and placenta after childbirth. These cells are primarily hematopoietic stem cells (HSCs), which have the ability to develop into various types of blood cells, including red blood cells, white blood cells, and platelets. Umbilical cord blood also contains mesenchymal stem cells (MSCs), which can differentiate into different cell types such as bone, cartilage, and fat cells. These stem cells are valuable for medical treatments, especially for regenerative medicine and transplant therapies, as they can be used to treat a range of conditions such as leukemia, lymphoma, blood disorders, and immune system diseases.

Stem Cell Umbilical Cord Blood Market Dynamics

Drivers

• Increasing Demand for Stem Cell Therapies

The increasing demand for stem cell therapies is a major driver in the stem cell umbilical cord blood market, fueled by the growing recognition of their effectiveness in treating a range of diseases such as blood disorders, cancer, and immune system conditions. According to the Global Cord Blood Corporation, over 80 diseases can be treated using stem cell transplants, which has led to greater investment in cord blood banking services and research. In addition, advancements in regenerative medicine, which use stem cells to repair or replace damaged tissues and organs, have driven this market expansion. For instance, mesenchymal stem cells (MSCs) from umbilical cord blood have shown promise in treating autoimmune diseases and injuries, increasing their value in medical applications. This rising demand has further been supported by statistics indicating that the global market for stem cell therapies is expected to reach USD 14.5 billion by 2027, showcasing the growing importance of umbilical cord blood as a vital resource for these treatments.

• Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases is a significant driver for the stem cell umbilical cord blood market, as these conditions increase the demand for effective treatment options. For instance, according to the World Health Organization (WHO), non-communicable diseases such as cancer, diabetes, and cardiovascular disorders account for nearly 71% of all deaths globally, underscoring the urgent need for advanced therapeutic solutions. Umbilical cord blood, which contains stem cells capable of regenerating damaged tissues and restoring healthy cell function, is increasingly seen as a viable alternative for treating diseases such as leukemia, lymphoma, blood disorders, and autoimmune conditions. The use of cord blood stem cells has been supported by clinical studies showing their success in transplant procedures, leading to an expansion in the number of cord blood banks and an increase in public and private sector investment in this field. This growing reliance on umbilical cord blood as a treatment option positions it as a vital component in the market's development.

 Opportunities

• Increasing Favorable Government Policies and Initiatives

Favorable government policies and initiatives have played a crucial role in bolstering the stem cell umbilical cord blood market, creating significant opportunities for growth. Governments around the world are increasingly recognizing the potential of stem cell research to advance medical treatments, which has resulted in increased funding and support for clinical studies and research institutions. For instance, the U.S. National Institutes of Health (NIH) has allocated substantial resources to stem cell research, contributing to the development of innovative therapies and protocols. Similarly, the European Union's Horizon 2020 program has funded numerous projects aimed at exploring stem cell-based regenerative medicine and its applications. These policy-driven investments promote the development of new technologies for umbilical cord blood collection, processing, and storage, leading to enhanced treatment options. Such support drives innovation and increases the accessibility and acceptance of umbilical cord blood therapies, positioning the market for further expansion and new opportunities.

• Improving Healthcare Infrastructure

Improving healthcare infrastructure in regions such as North America and Asia-Pacific is a significant market opportunity for the stem cell umbilical cord blood market, as it supports greater access to essential services for collection, processing, and storage. In North America, countries such as the United States and Canada have well-established healthcare systems with specialized hospitals and clinics equipped for stem cell collection and storage, contributing to the increased use of umbilical cord blood for medical treatments. For instance, CBR Systems, Inc., a leader in cord blood banking in the U.S., benefits from the region’s strong healthcare infrastructure to offer reliable services to families. Similarly, Asia-Pacific countries, including China and South Korea, are investing heavily in modernizing their healthcare facilities and expanding specialized medical centers, which facilitates better collection and use of cord blood. This improved infrastructure enables better patient access to stem cell therapies, positioning the market for expansion as more families are encouraged to bank cord blood for future use, thereby driving growth.

Restraints/Challenges

• Limited Awareness and Education

Limited awareness and education present a significant challenge in the stem cell umbilical cord blood market, hindering its growth and widespread adoption. Many expectant parents remain unaware of the potential benefits of cord blood banking or may have misconceptions about its effectiveness, leading to a lack of interest in preserving this resource. For instance, a 2018 study found that many parents are not informed about the potential life-saving uses of cord blood for treating conditions such as leukemia or immune disorders, which results in low participation rates in cord blood banking programs. Without proper education, people may overlook the option of public or private cord blood storage, even when it could benefit them or their families. The gap in knowledge also means that potential donors may not fully understand how public cord blood banks operate or how their donated stem cells can be used to help others in need. This limited awareness and education impede the market's expansion by reducing the overall uptake of cord blood banking services and fostering uncertainty about the value of stem cell treatments.

• High Costs and Accessibility

High costs and accessibility are significant challenges in the stem cell umbilical cord blood market, impacting its growth and wider adoption. Collecting, processing, and storing umbilical cord blood involves considerable expenses, which can make private cord blood banking unaffordable for many families, limiting access to those with financial means. While private cord blood banking offers exclusive access to stored stem cells, public banking options, where donations are shared for use in treatments, may not be widely available due to limited funding and storage capacity. This disparity in access perpetuates health inequities, particularly in developing regions, where families may not have the resources to bank their newborn's cord blood, despite its potential to treat diseases such as leukemia or certain blood disorders. The high costs and limited access create a barrier to fully realizing the benefits of cord blood stem cells, hindering market growth and the equitable distribution of potentially life-saving treatments.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Stem Cell Umbilical Cord Blood Market Scope

The market is segmented on the basis of storage service, therapeutics, and application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Storage Service

• Public Cord Blood Banks
• Private Cord Blood Banks
• Hybrid Cord Blood Banks

Therapeutics

• Cancer
• Diabetes
• Blood Diseases
• Immune Disorders
• Metabolic Disorders
• Other Diseases

Application

• Transplant Medicine
• Regenerative Medicine

Stem Cell Umbilical Cord Blood Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, storage service, therapeutics, and application as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the stem cell umbilical cord blood market, driven by substantial investments in research and development activities related to genetic testing. The region benefits from advanced healthcare infrastructure and significant support for scientific innovations. In addition, a favorable reimbursement framework further encourages the adoption and utilization of stem cell-based therapies. These factors collectively position North America as a dominant player in the global stem cell umbilical cord blood market.

Asia-Pacific is expected to experience the highest growth rate in the stem cell umbilical cord blood market during the forecast period, driven by an increasing prevalence of cancer and other chronic health conditions. Improvements in healthcare infrastructure and access to advanced medical technologies are also contributing to this growth. The region's expanding investment in medical research and treatment options further supports the adoption of stem cell therapies. These factors combined make Asia-Pacific a key area of rapid market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Stem Cell Umbilical Cord Blood Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Stem Cell Umbilical Cord Blood Market Leaders Operating in the Market Are:

• Cordlife (Singapore)
• CBR Systems, Inc. (U.S.)
• Cryo-Cell International, Inc. (U.S.)
• MEDIPOST (South Korea)
• Americord Registry (U.S.)
• LifeCell (India)
• Global Cord Blood Corporation (Hong Kong)
• ViaCord (U.S.)
• Vita 34 1997 - 2024, Inc. (Germany)
• Covis Pharma GmbH (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Takeda Pharmaceutical Company Limited (Japan)
• Cytori Therapeutics Inc. (U.S.)
• Athersys, Inc. (U.S.)
• Cord for Life (U.S.)
• Precision Cellular Storage Ltd. (Canada)

Latest Developments in Stem Cell Umbilical Cord Blood Market

• In March 2023, LifeCell International, an Indian company, introduced the 'PrepaCyte-CB' cord blood processing technology, ensuring the growing stem cell yield
• In October 2021, Americord Registry LLC, a U.S.-based biotechnology firm, opened a new research and development (R&D) and cell processing laboratory in New York City. The facility aims to innovate regenerative medicine solutions, advancing stem cell applications for treating cancers, neurological disorders, and autoimmune conditions
• In September 2021, CBR Systems, Inc., a U.S.-based newborn stem cell bank, announced that over 10,000 families had joined the Newborn Possibilities Program (NPP). This initiative focuses on preserving umbilical cord blood for children diagnosed with serious conditions or at risk of pediatric developmental disabilities, while also providing healthcare providers with training to identify potential candidates for stem cell treatments
• In October 2020, American Cryostem Corp, a U.S.-based biotechnology company, partnered with BioTherapeutic Labs (BTL) Corp., an umbilical cord tissue manufacturing company. The collaboration focuses on marketing CRYO's autologous mesenchymal stem cell products and advancing R&D protocols using BTL's umbilical cord-based product lines, expanding market reach and demand for cord blood services
• In August 2020, CBR Systems, Inc., a U.S.-based private newborn stem cell bank, collaborated with NantKwest Inc., a clinical-stage immunotherapy company, to develop a COVID-19 treatment using newborn stem cells. CBR provided umbilical cord tissue-derived mesenchymal stem cells (MSCs) to NantKwest for expansion through its proprietary bioreactor system, highlighting the growing demand for cord blood applications

SKU-61714